US Bancorp’s Cymabay Therapeutics CBAY Stock Holding History

US Bancorp’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-28,986	Closed	-$685K	–	4141
2023 Q4	$685K	Sell	28,986 -16,071	-36%	-$286K	﹤0.01%	1319
2023 Q3	$672K	Buy	+45,057	New	+$597K	﹤0.01%	1220
2023 Q2	–	Sell	-360	Closed	-$3.14K	–	4168
2023 Q1	$3.14K	Buy	+360	New	+$2.88K	﹤0.01%	3660
2021 Q1	–	Sell	-1,333	Closed	-$8K	–	3988
2020 Q4	$8K	Buy	+1,333	New	+$10.1K	﹤0.01%	3284
2019 Q2	–	Sell	-500	Closed	-$7K	–	3691
2019 Q1	$7K	Hold	500	–	–	﹤0.01%	3162
2018 Q4	$4K	Buy	+500	New	+$4.76K	﹤0.01%	3283
2018 Q3	–	Sell	-500	Closed	-$7K	–	3719
2018 Q2	$7K	Buy	+500	New	+$6.26K	﹤0.01%	3251

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

US Bancorp's CBAY Position: Q1 2024 in Review

US Bancorp sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 28,986 shares — an estimated $685K sold.

US Bancorp first reported a position in CBAY in Q2 2018 and held it in 7 quarters. The position peaked at $685K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

US Bancorp reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
US Bancorp sold 28,986 Cymabay Therapeutics shares in Q1 2024, an estimated $685K.
US Bancorp first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 7 quarters.
US Bancorp's Cymabay Therapeutics position peaked at $685K in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.